Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Buy” by Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $47.00.

Several brokerages recently weighed in on COLL. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Truist Financial increased their price target on Collegium Pharmaceutical from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. HC Wainwright upped their target price on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Finally, Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 21st.

Insider Buying and Selling

In other news, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. This trade represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. This represents a 14.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 51,250 shares of company stock valued at $2,235,352. Company insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of COLL. Federated Hermes Inc. boosted its stake in shares of Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares during the period. CWM LLC lifted its holdings in Collegium Pharmaceutical by 453.9% during the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 1,153 shares in the last quarter. Hantz Financial Services Inc. boosted its position in Collegium Pharmaceutical by 137.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after acquiring an additional 2,190 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 368.9% during the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock worth $82,000 after acquiring an additional 2,169 shares during the period.

Collegium Pharmaceutical Trading Down 0.6%

Shares of COLL opened at $48.71 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical has a 12-month low of $23.23 and a 12-month high of $49.49. The firm has a 50-day moving average price of $41.31 and a 200 day moving average price of $36.30. The firm has a market capitalization of $1.54 billion, a P/E ratio of 30.25 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The company had revenue of $135.55 million for the quarter. Sell-side analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.